Development of a dry powder inhaler dispersion mechanism

干粉吸入器分散机构的开发

• 批准号: 6693189
• 负责人: TIMOTHY M. CROWDER
• 金额: $ 9.72万
• 依托单位: ORIEL THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-04 至 2004-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6693189
• 关键词: aerosols; dosage forms; drug delivery systems; drug design /synthesis /production; inhalation drug administration; solid state; sound frequency; technology /technique development

DESCRIPTION (provided by applicant): Oriel Therapeutics, Inc. is developing a dry powder inhaler (DPI) technology that will drive a fundamental change in how the majority of aerosol drugs are delivered. The key technological innovations are in the use of techniques for aerosol generation that are specific to the powder and a novel disposable active aerosol generation mechanism. Oriel's DPI could replace pressurized metered dose inhalers (pMDIs) and will decrease development time and costs for new pharmaceutical aerosol formulations. The long-term goal of the Oriel development program is the production of a DPI technology platform that would allow Oriel to partner with pharmaceutical companies with a new molecule for aerosol drug delivery. This application proposes the generation of performance data for the Oriel DPI that will unequivocally support the claim that the Oriel technology is superior to current DPIs and is a viable pMDI replacement. These data will be generated through the formulation of a matrix of model drugs representing a broad range of powder flow properties. These powders will be characterized and the Oriel technology to disperse the formulations built around the measured properties. The technology will then be applied to the generation of critical performance data for the range of formulations.

描述（由申请人提供）：Oriel Therapeutics, Inc.正在开发一种干粉吸入器（DPI）技术，该技术将推动大多数气雾剂药物的输送方式发生根本性变化。关键的技术创新在于使用粉末专用的气溶胶生成技术和新型一次性主动气溶胶生成机制。 Oriel 的 DPI 可以取代加压计量吸入器 (pMDI)，并将减少新药物气雾剂配方的开发时间和成本。 Oriel 开发计划的长期目标是生产 DPI 技术平台，使 Oriel 能够与制药公司合作开发用于气雾剂药物输送的新分子。该应用建议为 Oriel DPI 生成性能数据，这将明确支持 Oriel 技术优于当前 DPI 并且是可行的 pMDI 替代品的主张。这些数据将通过代表广泛的粉末流动特性的模型药物矩阵的配制来生成。这些粉末将被表征，并采用 Oriel 技术来分散围绕测量的特性构建的配方。然后，该技术将应用于生成一系列配方的关键性能数据。